These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 26763357)
1. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients. García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836 [TBL] [Abstract][Full Text] [Related]
3. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma]. Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871 [TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV). Holzhey T; Pönisch W; Wang SY; Holzvogt M; Holzvogt B; Andrea M; Zehrfeld T; Hammerschmidt D; Hoffmann FA; Becker C; Schwarzer A; Schwarz M; Schönfelder-Fricke U; Edelmann T; Braunert L; Franke GN; Jentzsch M; Schwind S; Bill M; Grimm J; Remane Y; Platzbecker U; Scholz M J Cancer Res Clin Oncol; 2021 Aug; 147(8):2349-2359. PubMed ID: 33433659 [TBL] [Abstract][Full Text] [Related]
5. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma]. Li ZQ; Tian WW; Guo YF; Ma LM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406 [TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials. Lopez-Anglada L; Cueto-Felgueroso C; Rosiñol L; Oriol A; Teruel AI; Lopez de la Guia A; Bengoechea E; Palomera L; de Arriba F; Hernandez JM; Granell M; Peñalver FJ; Garcia-Sanz R; Besalduch J; Gonzalez Y; Martinez RB; Hernandez MT; Gutierrez NC; Puerta P; Valeri A; Paiva B; Blade J; Mateos MV; San Miguel J; Lahuerta JJ; Martinez-Lopez J; PLoS One; 2018; 13(9):e0203392. PubMed ID: 30192814 [TBL] [Abstract][Full Text] [Related]
7. Serum Free Light Chain Predict Overall Survival and Response to Therapy in Patients with Newly Diagnosed Multiple Myeloma. Meddour Y; Rahali MC; Belakehal SE; Ardjoun FZ; Chaib S; Djidjik R Clin Lab; 2018 Apr; 64(4):551-558. PubMed ID: 29739080 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464 [TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495 [TBL] [Abstract][Full Text] [Related]
11. Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains. Xu Y; Sui W; Deng S; An G; Wang Y; Xie Z; Yao H; Zhu G; Zou D; Qi J; Hao M; Zhao Y; Wang J; Chen T; Qiu L Leuk Lymphoma; 2013 Jan; 54(1):123-32. PubMed ID: 22712834 [TBL] [Abstract][Full Text] [Related]
12. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735 [TBL] [Abstract][Full Text] [Related]
13. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Dytfeld D; Griffith KA; Friedman J; Lebovic D; Harvey C; Kaminski MS; Jakubowiak AJ Leuk Lymphoma; 2011 Jul; 52(7):1271-80. PubMed ID: 21699382 [TBL] [Abstract][Full Text] [Related]
14. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Hwa YL; Dingli D; Kapoor P; Hayman SR; Lust JA; Kyle RA; Kumar SK Leukemia; 2015 Oct; 29(10):2033-8. PubMed ID: 25962523 [TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma. Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919 [TBL] [Abstract][Full Text] [Related]
16. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients. Yağcı M; Karakaya F; Suyanı E; Haznedar R Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109 [TBL] [Abstract][Full Text] [Related]
17. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517 [TBL] [Abstract][Full Text] [Related]
18. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. Guo Z; Li H; Geng Y; Cui J; Tang N; Li D Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348 [TBL] [Abstract][Full Text] [Related]
19. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction. Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Hansen CT; Pedersen PT; Nielsen LC; Abildgaard N Eur J Haematol; 2014 Nov; 93(5):407-13. PubMed ID: 24809596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]